Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · Real-Time Price · USD
5.79
+0.08 (1.40%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Aura Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aura Biosciences stock have an average target of 22.75, with a low estimate of 19 and a high estimate of 25. The average target predicts an increase of 292.92% from the current stock price of 5.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aura Biosciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $21 → $19 | Buy | Maintains | $21 → $19 | +228.15% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $25 | Strong Buy | Maintains | $22 → $25 | +331.78% | Mar 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +279.97% | Mar 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +279.97% | Nov 14, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $20 → $23 | Buy | Maintains | $20 → $23 | +297.24% | Oct 18, 2024 |
Financial Forecast
Revenue This Year
n/a
from 247.20M
Revenue Next Year
n/a
EPS This Year
-2.20
from -1.75
EPS Next Year
-2.35
from -2.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 36.8M | ||
| Avg | n/a | n/a | 23.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.89 | -1.94 | -1.72 |
| Avg | -2.20 | -2.35 | -2.50 |
| Low | -2.47 | -2.67 | -3.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.